2-Naphthalenesulphonyl L-aspartyl-(2-phenethyl)amide (2-NAP)--a selective cholecystokinin CCKA-receptor antagonist - Wikidata - wikimedia - TriplyDB

2-Naphthalenesulphonyl L-aspartyl-(2-phenethyl)amide (2-NAP)--a selective cholecystokinin CCKA-receptor antagonist

2-Naphthalenesulphonyl L-aspartyl-(2-phenethyl)amide (2-NAP)--a selective cholecystokinin CCKA-receptor antagonist

http://www.wikidata.org/entity/Q41866496

about

Characterization of the binding of a novel radioligand to CCKB/gastrin receptors in membranes from rat cerebral cortex Effects of peripheral CCK receptor blockade on feeding responses to duodenal nutrient infusions in rats Cholecystokinin antagonists: pharmacological and therapeutic potential.Molecular cloning, expression and pharmacological characterization of the canine cholecystokinin 1 receptor PEGylated cholecystokinin prolongs satiation in rats: dose dependency and receptor involvement.Unexpected relationship between plasma protein binding and the pharmacodynamics of 2-NAP, a CCK1-receptor antagonist.PEGylated cholecystokinin is more potent in inducing anorexia than conditioned taste aversion in rats.Analysis of variation in L-365,260 competition curves in radioligand binding assays 2-Naphthalenesulphanyl-L-aspartyl-2-(phenethyl) amide (2-NAP) and food intake in rats: evidence that endogenous peripheral CCK does not play a major role as a satiety factor.Pharmacological evidence for putative CCK(1) receptor heterogeneity in human colon smooth muscle.Effects of peripheral CCK receptor blockade on food intake in rats.Relative blood-brain barrier permeabilities of the cholecystokinin receptor antagonists devazepide and A-65186 in rats.Cholecystokinin-A receptor antagonists: therapies for gastrointestinal disorders.

P2860

Q28343282-24E24B8A-48A8-421D-9432-661F64E6BCDA Q28578998-B1B80F26-4F11-4858-8F98-044EF13E9475 Q34203535-DDB0582D-6515-4E51-9ABC-11E709947E1C Q35048902-BB05EC68-50A5-4077-87BA-09EC18F017BB Q36094371-C129F0F4-2EE5-4C1C-8F35-FD31B28A0CE5 Q38508311-1C7960E5-C9CB-4A72-A4CE-63BED6A01F61 Q41810707-CE7F66AE-8DD7-4A58-9E3F-C195C648E78E Q41823935-C431C894-96A7-4452-9FF3-778371848B54 Q41903306-5477198E-6DC0-423D-943F-55E644F7F769 Q43263725-2968045A-1F2E-4F88-8707-22A91EFB9540 Q44435084-B63CC35C-E03B-4D5B-8740-015A08209A43 Q48102294-FA49C9C7-D81A-4EE6-A362-541421EE60AA Q48660973-5368BA6A-FD2C-44B4-A18B-02B18ACB405C

P2860

2-Naphthalenesulphonyl L-aspartyl-(2-phenethyl)amide (2-NAP)--a selective cholecystokinin CCKA-receptor antagonist

http://www.wikidata.org/entity/Q41866496

description

1993 nî lūn-bûn

@nan

1993年の論文

@ja

1993年論文

@yue

1993年論文

@zh-hant

1993年論文

@zh-hk

1993年論文

@zh-mo

1993年論文

@zh-tw

1993年论文

@wuu

1993年论文

@zh

1993年论文

@zh-cn

name

2-Naphthalenesulphonyl L-aspar ...... kinin CCKA-receptor antagonist

@en

type

label

2-Naphthalenesulphonyl L-aspar ...... kinin CCKA-receptor antagonist

@en

prefLabel

2-Naphthalenesulphonyl L-aspar ...... kinin CCKA-receptor antagonist

@en

P1433

Q41866496-7A27B8A5-7FF4-4347-8AFD-ACD8C45A126D

P1476

Q41866496-5F5B4E57-7362-4469-A61F-4753261B763F

P2093

Q41866496-99283FBA-15EA-4990-B250-B6D9211E3472

Q41866496-A30F995F-E8E3-454A-8829-2EBBFF83C6B3

Q41866496-BE0BE7A0-67E6-47C2-A2F5-EE9310ACC2AC

Q41866496-C0C6B936-F1AE-4485-A1B8-93969B2E6BAC

Q41866496-FD7F97DD-B7BF-4CC9-A5E9-6724530EADBF

P2860

Q41866496-0344CFCF-2A63-44B0-AF62-8B6AB03236B0

Q41866496-0C3CCA07-2244-404A-8F45-74CF6CFB22EE

Q41866496-11AE8CE5-2DC3-4329-8ACC-1BE7DA9B1304

Q41866496-189C2FBC-16B3-4254-8D41-15F620B014F9

Q41866496-340F1D78-0A93-4598-B08C-928469195DDF

Q41866496-374E3B07-F2EE-4684-B8F4-33F9956E750E

Q41866496-3AB6F34E-6E0F-4930-B66B-DD1168848701

Q41866496-41584652-A86B-418F-9759-AB071682F653

Q41866496-4232AB1F-FAEE-411F-8814-0A57B65742C9

Q41866496-4E2EBF67-C09A-46E7-9CAE-9DAD562F4847

P304

Q41866496-1F73545D-E192-4F61-8346-FBD81778A2E1

P31

Q41866496-35D7BFA4-D24B-4685-B585-523DD2B02F23

P356

Q41866496-C724BAD3-4672-4566-9CB6-5E536B297522

P407

Q41866496-A0C03B84-3E63-4D70-A873-9492D2380CEA

P433

Q41866496-6ACD2161-84FB-4EF3-9917-167AA0756148

P478

Q41866496-17633A33-1BB3-42AC-A34D-DE239CA66AB1

P577

Q41866496-BD550235-FB14-4067-9595-1530EFFAE742

P5875

Q41866496-83ABF362-88DD-407A-A094-C53FFFB7A72F

P698

Q41866496-429C834D-5F2F-4DA9-9A4A-0963572A1CBB

P921

Q41866496-B8E3DEDC-8A77-474B-8140-B7A677F825C2

P932

Q41866496-FAB6BEE9-5DC5-479E-8343-C92C5FC980D8

P356

J.1476-5381.1993.TB12870.X

P1433

British Journal of Pharmacology

P1476

2-Naphthalenesulphonyl L-aspar ...... kinin CCKA-receptor antagonist

@en

P2093

Black JW

http://www.w3.org/2001/XMLSchema#string

Gerkowitch VP

http://www.w3.org/2001/XMLSchema#string

Harper EA

http://www.w3.org/2001/XMLSchema#string

Hull RA

http://www.w3.org/2001/XMLSchema#string

Shankley NP

http://www.w3.org/2001/XMLSchema#string

P2860

Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity

Benzodiazepine analogues L365,260 and L364,718 as gastrin and pancreatic CCK receptor antagonists

A specific competitive inhibitor of angiotensin II.

Structure-function relationships in the active C-terminal tetrapeptide sequence of gastrin.

Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist.

Studies of three non-peptide cholecystokinin antagonists (devazepide, lorglumide and loxiglumide) in human isolated alimentary muscle and guinea-pig ileum.

Cholecystokinin antagonists.

Pharmacological analysis of beta-adrenoceptor-mediated agonism in the guinea-pig, isolated, right atrium.

Combined dose-ratio analysis of cholecystokinin receptor antagonists, devazepide, lorglumide and loxiglumide in the guinea-pig gall bladder

Further analysis of anomalous pKB values for histamine H2-receptor antagonists on the mouse isolated stomach assay.

P304

734-740

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1476-5381.1993.TB12870.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P577

1993-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

15517300

http://www.w3.org/2001/XMLSchema#string

P698

7682135

http://www.w3.org/2001/XMLSchema#string

P921

Cholecystokinin

P932

1908054

http://www.w3.org/2001/XMLSchema#string